AEDG is a small hydrophilic tetrapeptide with negligible plasma-protein binding, no documented cytochrome-P450 (CYP) metabolism, and no described interaction with organic-anion or organic-cation transporter families
The presence of certain syalilated isoforms of Serpin A1 in the CSF has been related with the development of dementia in PD patients (Jesse et al., 2012)
These were not all head-to-head trials
Potential Benefits of AOD-9604 Targeted Fat Reduction Directly stimulates the breakdown of stored fat in adipose tissue, particularly in stubborn areas resistant to diet and exercise Inhibited Fat Formation Prevents the creation of new fat cells, supporting long-term body composition improvements beyond initial fat loss No Blood Sugar Impact Does not affect glucose metabolism or insulin sensitivity, making it safe for patients concerned about metabolic disruption No IGF-1 Stimulation Avoids the cell proliferation effects associated with full HGH therapy while retaining the fat-specific benefits Improved Body Composition Helps shift the ratio of fat to lean tissue for a more defined, healthier physique Complementary to Diet and Exercise Enhances results from nutrition and training programs by targeting fat at the cellular level Potential Joint Support Emerging research suggests AOD-9604 may support cartilage health and repair Well-Tolerated Safety Profile Decades of research support AOD-9604's safety for fat reduction applications without significant adverse effects What Is AOD-9604 For
Several meta-analyses of observational studies have found elevated blood concentrations of homocysteine to be linked with an increased risk of dementia (74) or Alzheimers disease (68, 75-78)
Improved Metabolism: B12 injections support the bodys metabolic processes, aiding in the breakdown of fats and proteins for energy
